Myolex Inc. develops devices used to assess muscle condition. Leveraging our large database of nearly 10 million muscle scans, Myolex’s patented technology, Electrical Impedance Myography (EIM), supports a vast and growing potential of applications ranging from elite athletics, sports medicine & physical therapy, medical orthopedics, and clinical research of neuromuscular diseases. With technology originally developed by Harvard Neurology Professor, Dr. Seward Rutkove, Myolex collaborates with clinical researchers and pharmaceutical companies to enhance their data-gathering capabilities for neuromuscular clinical trials. In addition, Myolex's technology is able to analyze fitness-related changes in the muscle, enabling coaches to design workouts with a better focus, and physical therapists to better diagnose, monitor, and advise on muscle injury. Myolex’s “EIM”/ “Muscle Quality/MQ” technology provided to Pharma, Physicians, & Patients, can create value for practices, patients, and many Pharma “trials”, resulting in better healthcare and lower total costs. Used in Pharma trials can save millions of $dollars in monitoring and tracking costs, due to better data and analysis, and faster trials with less time and less people involved with more & better data, measured more often, and easier to get. lt can also be done by the patient at home, even during a Pandemic! Use of mScan by physicians will improve quality of care via more accurate and efficient monitoring of muscle health as a MQ “vital sign”, both for predictive values and during treatments, for things like surgery appropriateness, timing, & outcomes, as well as monitoring recovery from procedures. “EIM” technology, via the mScan, is a solution that creates value in the medical marketplace. EIM supports a vast and growing set of applications ranging from physicians to Physical Therapy, and medical orthopedics to clinical research of neuromuscular diseases.